Half-year report · HY
6523.TEDINET S100X235
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥173.4bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥361.6bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥173.9bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥10.4bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥941m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥18.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥559m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥692m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥525.8bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥532.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥525.4bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥379.8bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥391.3bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥146.0bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥141.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥127.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥146.7bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥141.6bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥127.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥39.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥33.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥12.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.9bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥17.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-4.42 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥83.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥32.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-4.42 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥82.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥32.42 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 27.9% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.3% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.2bn |
| Diabetes Managementreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥48.7bn |
| Diabetes Managementreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥48.7bn |
| Diabetes Managementreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥9.3bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥59.1bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥59.1bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Healthcare Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥62.7bn |
| Healthcare Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥62.7bn |
| Healthcare Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥170.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥170.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥13.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.3bn |
| Diabetes Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 753
| Item | Context | Value | Unit |
|---|---|---|---|
| Property plant and equipment IFRS | Prior1YearInstant | 48374000000 | JPY |
| Property plant and equipment IFRS | InterimInstant | 44286000000 | JPY |
| Goodwill IFRS | Prior1YearInstant | 206500000000 | JPY |
| Goodwill IFRS | InterimInstant | 212100000000 | JPY |
| Intangible assets IFRS | Prior1YearInstant | 80649000000 | JPY |
| Intangible assets IFRS | InterimInstant | 76688000000 | JPY |
| Investments accounted for using equity method IFRS | Prior1YearInstant | 1821000000 | JPY |
| Investments accounted for using equity method IFRS | InterimInstant | 1006000000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 13932000000 | JPY |
| Other financial assets nca IFRS | InterimInstant | 12113000000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 6120000000 | JPY |
| Deferred tax assets IFRS | InterimInstant | 8183000000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 2293000000 | JPY |
| Other non current assets nca IFRS | InterimInstant | 2382000000 | JPY |
| Non current assets IFRS | Prior1YearInstant | 359691000000 | JPY |
| Non current assets IFRS | InterimInstant | 356762000000 | JPY |
| Assets IFRS | Prior1YearInstant | 532482000000 | JPY |
| Assets IFRS | InterimInstant | 525819000000 | JPY |
| Trade and other payables cl IFRS | Prior1YearInstant | 65665000000 | JPY |
| Trade and other payables cl IFRS | InterimInstant | 67093000000 | JPY |
| Borrowings cl IFRS | Prior1YearInstant | 34278000000 | JPY |
| Borrowings cl IFRS | InterimInstant | 245011000000 | JPY |
| Income taxes payable cl IFRS | Prior1YearInstant | 4207000000 | JPY |
| Income taxes payable cl IFRS | InterimInstant | 3350000000 | JPY |
| Provisions cl IFRS | Prior1YearInstant | 7725000000 | JPY |
| Provisions cl IFRS | InterimInstant | 7759000000 | JPY |
| Other financial liabilities cl IFRS | Prior1YearInstant | 5812000000 | JPY |
| Other financial liabilities cl IFRS | InterimInstant | 5309000000 | JPY |
| Other current liabilities cl IFRS | Prior1YearInstant | 22865000000 | JPY |
| Other current liabilities cl IFRS | InterimInstant | 19113000000 | JPY |
| Total current liabilities IFRS | Prior1YearInstant | 140555000000 | JPY |
| Total current liabilities IFRS | InterimInstant | 347637000000 | JPY |
| Trade and other payables ncl IFRS | Prior1YearInstant | 597000000 | JPY |
| Trade and other payables ncl IFRS | InterimInstant | 597000000 | JPY |
| Borrowings ncl IFRS | Prior1YearInstant | 220982000000 | JPY |
| Borrowings ncl IFRS | InterimInstant | 2680000000 | JPY |
| Retirement benefit liability ncl IFRS | Prior1YearInstant | 5544000000 | JPY |
| Retirement benefit liability ncl IFRS | InterimInstant | 5748000000 | JPY |
| Provisions ncl IFRS | Prior1YearInstant | 4575000000 | JPY |
| Provisions ncl IFRS | InterimInstant | 4599000000 | JPY |
| Other financial liabilities ncl IFRS | Prior1YearInstant | 8358000000 | JPY |
| Other financial liabilities ncl IFRS | InterimInstant | 7022000000 | JPY |
| Deferred tax liabilities IFRS | Prior1YearInstant | 9291000000 | JPY |
| Deferred tax liabilities IFRS | InterimInstant | 10040000000 | JPY |
| Other non current liabilities ncl IFRS | Prior1YearInstant | 1405000000 | JPY |
| Other non current liabilities ncl IFRS | InterimInstant | 1450000000 | JPY |
| Non current labilities IFRS | Prior1YearInstant | 250755000000 | JPY |
| Non current labilities IFRS | InterimInstant | 32140000000 | JPY |
| Liabilities IFRS | Prior1YearInstant | 391310000000 | JPY |
| Liabilities IFRS | InterimInstant | 379777000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |